US10966950B2

Use of an RXR agonist in treating HER2+ cancers

University of Texas System

Abstract

The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.

University: University of Texas System
Assignee: Board Of Regents, The University Of Texas System
Inventor: Martin E. Sanders
Priority date: June 11, 2019
Filing date: June 10, 2020
Grant date: April 06, 2021
Publication date: April 06, 2021
Language: en
PDF source: https://patentimages.storage.googleapis.com/15/28/d0/f4308cf581a41c/US10966950.pdf
Metadata fetched: August 29, 2026 00:28